What insurance policy changes affect HCPCS J7512?

There are 12 tracked policy changes affecting HCPCS J7512, including updates from Aetna. Each change may modify coverage criteria, reimbursement rates, or prior-authorization requirements.

Which payers have updated policy for HCPCS J7512?

Payers that have issued tracked updates for HCPCS J7512 include: Aetna.

How do I get notified when HCPCS J7512 policy changes?

Create a free account at PolicyChanges.app and save a search filtered to HCPCS J7512. You will receive a daily digest email whenever a new policy change references this code.

Why do payers change policies for HCPCS J7512?

Payers revise policies for individual billing codes to align with updated clinical guidelines, CMS rule changes, fraud and abuse prevention measures, or network cost-management goals. Changes can affect medical necessity criteria, place-of-service restrictions, bundling rules, or whether a code requires prior authorization.

J7512 Insurance Policy Changes

HCPCS J7512 is officially defined as "Prednisone, immediate release or delayed release, oral, 1 mg." HCPCS J7512 is referenced in 12 tracked payer policy changes from Aetna. For billers and coders, staying current on payer-specific coverage criteria, reimbursement rules, and prior-authorization requirements for HCPCS J7512 is critical to clean claim submission. Each entry below links to the full policy analysis with effective dates and action steps.

High impact
Rozanolixizumab-noli (Rystiggo) (CPB 1035, reviewed 2026-08-11)
Aetna·Effective Aug 11, 2026
Aetna has established a new medical policy (CPB 1035) for Rozanolixizumab-noli (Rystiggo), a neonatal Fc receptor blocker for generalized myasthenia gravis. The policy requires precertification before treatment, restricts prescribing to neurologists, and establishes specific clinical criteria including antibody positivity, MGFA classification II-IV, MG-ADL score ≥5, and documented failure of at least two immunosuppressive therapies or one immunosuppressive plus IVIG over 12 months. Billing teams must implement prior authorization workflows and track the new HCPCS code J9333.
High impact
Reslizumab (Cinqair) (CPB 0907, reviewed 2026-08-10)
Aetna·Effective Aug 10, 2026
Aetna updated its reslizumab (Cinqair) coverage policy for severe asthma treatment, effective immediately. The policy requires precertification for all commercial plans, restricts prescribing to allergists/immunologists or pulmonologists, and mandates specific clinical criteria including baseline eosinophil counts ≥400 cells/mcL or oral corticosteroid dependence, plus documented uncontrolled asthma despite high-dose ICS and additional controller therapy. Billing teams must implement prior authorization workflows and ensure claims include appropriate documentation before submission.
High impact
Tezepelumab-ekko (Tezspire) (CPB 1003, reviewed 2026-08-06)
Aetna·Effective Aug 6, 2026
Aetna has issued a NEW medical policy (CPB 1003, effective 2026-08-06) establishing coverage criteria for Tezepelumab-ekko (Tezspire) for severe asthma and chronic rhinosinusitis with nasal polyps in members 12+. The policy requires precertification for all members, mandates trial of lower-cost biologics first (when available), and restricts prescribing to allergists/immunologists, pulmonologists, or otolaryngologists. Billing teams must immediately implement prior authorization workflows and update coding systems.
High impact
Belimumab (Benlysta) (CPB 0818, reviewed 2026-06-10)
Aetna·Effective Jun 10, 2026
Aetna has updated its Belimumab (Benlysta) clinical policy effective June 10, 2026, establishing mandatory precertification requirements, specific approval criteria for SLE and lupus nephritis treatment, specialist prescriber requirements, and clear exclusions for CNS lupus and biologic combination therapy. Billing teams must implement precertification workflows and ensure claims meet the defined clinical criteria before submission.
High impact
Anifrolumab-fnia (Saphnelo) (CPB 0997, reviewed 2026-06-05)
Aetna·Effective Jun 5, 2026
Aetna has issued a new clinical policy (CPB 0997, effective 2026-06-05) establishing coverage criteria for anifrolumab-fnia (Saphnelo) for moderate to severe systemic lupus erythematosus (SLE) in adults. The policy requires precertification for all Aetna participating providers, mandatory rheumatology consultation, specific autoantibody confirmation, and concurrent standard SLE therapy. Coverage explicitly excludes severe active lupus nephritis, severe CNS lupus, and concurrent biologic use.
High impact
Polatuzumab Vedotin-piiq (Polivy) (CPB 0955, reviewed 2026-09-17)
Aetna·Identified Sep 30, 2026
Aetna has established updated coverage criteria for Polatuzumab Vedotin-piiq (Polivy) for treatment of multiple B-cell lymphoma subtypes, including DLBCL, high-grade B-cell lymphomas, and post-transplant lymphoproliferative disorders. All uses require mandatory precertification before administration. Coverage is limited to up to 6 cycles total, with specific combinations and clinical scenarios defined for initial and continuation therapy.
Medium impact
Siltuximab (Sylvant) (CPB 0884, reviewed 2026-06-03)
Aetna·Effective Jun 3, 2026
Aetna updated its coverage policy for siltuximab (Sylvant) effective June 3, 2026, establishing medical necessity criteria for two primary indications: Castleman's disease (multicentric and unicentric relapsed/refractory forms) and cytokine release syndrome (including CAR T-cell, lymphocyte engager, and KSHV-associated). The policy also clarifies continuation of therapy requirements and designates 20+ other cancer and inflammatory conditions as experimental/investigational. Billing teams must verify member eligibility against specific disease criteria before claim submission.
Medium impact
Remestemcel-L-rknd (Ryoncil) (CPB 1077, reviewed 2026-05-27)
Aetna·Effective May 27, 2026
Aetna has established a new coverage policy for Remestemcel-L-rknd (Ryoncil), an FDA-approved mesenchymal stromal cell therapy for steroid-refractory acute graft-versus-host disease (aGVHD) in pediatric patients. The policy permits a maximum of 8 initial infusions plus up to 4 additional infusions for partial response or 8 infusions for recurrence, contingent on meeting specific steroid-refractory criteria. All Ryoncil infusions require precertification before administration.
Medium impact
Guillain-Barre Syndrome Treatments (CPB 0732, reviewed 2026-10-21)
Aetna·Identified Oct 26, 2026
This is a policy review (not a change) of Aetna's Clinical Policy Bulletin 0732 on Guillain-Barré Syndrome treatments, last reviewed 2026-10-21. The policy specifies that IVIG, plasmapheresis, and pulmonary rehabilitation are medically necessary when criteria in related CPBs are met, while corticosteroids, eculizumab, rituximab, and other agents remain experimental/investigational. No effective date or policy modification is stated in the source document.
Medium impact
Rilonacept (Arcalyst) (CPB 0770, reviewed 2026-09-11)
Aetna·Identified Oct 3, 2026
Aetna issued a fresh clinical policy (CPB 0770) for Rilonacept (Arcalyst) effective immediately, establishing coverage criteria for three indications: Cryopyrin-associated periodic syndromes (CAPS) in members 12+, Deficiency of interleukin-1 receptor antagonist (DIRA) in members 10kg+, and Recurrent pericarditis (RP) in members 12+. All other uses are considered experimental/investigational. The policy requires specific prescriber credentials by specialty and mandates TB screening before initiation.
Medium impact
Vitiligo (CPB 0422, reviewed 2026-07-16)
Aetna·Identified Aug 19, 2026
Aetna updated its vitiligo treatment policy (CPB 0422) to establish medical necessity criteria for photochemotherapy, excimer laser, and narrow-band UVB therapies, requiring documented inadequate response to topical tacrolimus, corticosteroids, or ruxolitinib before approval. The policy designates numerous treatments as experimental/investigational (including JAK inhibitors combined with UVB, CAR-T therapy, rituximab, and various grafting techniques) and classifies micropigmentation and depigmentation as cosmetic, not covered.
Medium impact
Mogamulizumab-kpkc (Poteligeo) (CPB 0940, reviewed 2026-04-28)
Aetna·Identified Aug 16, 2026
Aetna has issued a fresh medical policy (CPB 0940, reviewed 2026-04-28) establishing coverage criteria for mogamulizumab-kpkc (Poteligeo) intravenous infusion for treating Adult T-cell leukemia/lymphoma (ATLL) and cutaneous T-cell lymphomas (mycosis fungoides and Sézary syndrome). This policy defines specific approved indications, dosing schedules (1 mg/kg IV infusion), and continuation-of-therapy criteria, with all other indications classified as experimental/investigational. Billing teams must implement coverage validation and prior authorization procedures for HCPCS code J9204 when claims are submitted.

All billing codes J3590 C9399 J3490 99213 99214 99212

Get alerts for changes like this

Save a search and receive a daily digest whenever a new policy change matches your filters.

Create a free alert

Rozanolixizumab-noli (Rystiggo) (CPB 1035, reviewed 2026-08-11)

Reslizumab (Cinqair) (CPB 0907, reviewed 2026-08-10)

Tezepelumab-ekko (Tezspire) (CPB 1003, reviewed 2026-08-06)

Belimumab (Benlysta) (CPB 0818, reviewed 2026-06-10)

Anifrolumab-fnia (Saphnelo) (CPB 0997, reviewed 2026-06-05)

Polatuzumab Vedotin-piiq (Polivy) (CPB 0955, reviewed 2026-09-17)

Siltuximab (Sylvant) (CPB 0884, reviewed 2026-06-03)

Remestemcel-L-rknd (Ryoncil) (CPB 1077, reviewed 2026-05-27)

Guillain-Barre Syndrome Treatments (CPB 0732, reviewed 2026-10-21)

Rilonacept (Arcalyst) (CPB 0770, reviewed 2026-09-11)

Vitiligo (CPB 0422, reviewed 2026-07-16)

Mogamulizumab-kpkc (Poteligeo) (CPB 0940, reviewed 2026-04-28)